DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado
Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre, BrasilPublicaciones en colaboración con investigadores/as de Pontifícia Universidade Católica do Rio Grande do Sul (6)
2024
-
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Annals of Oncology, Vol. 35, Núm. 11, pp. 1026-1038
2022
-
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer, Vol. 128, Núm. 11, pp. 2085-2097
2020
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588
-
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
European Journal of Cancer, Vol. 138, pp. 202-211
2018
-
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma
New England Journal of Medicine, Vol. 378, Núm. 14, pp. 1277-1290
-
The clinical activity of PD-1/PD-L1 inhibitors in metastatic non–clear cell renal cell carcinoma
Cancer Immunology Research, Vol. 6, Núm. 7, pp. 758-765